home > ict > autumn 2019 > the burden of time
International Clinical Trials

The Burden of Time

“Burdens are for shoulders strong enough to carry them” Margaret Mitchell

There is a general consensus of the need to increase the opportunities for patients and their family members to take part in appropriate research. This is because the range of patient groups and supporter experiences are pivotal to the success of studies and the confident extrapolation of data. Similarly, improving participant retention is also a key concern, and there is a drive to ensure, rightly, that patients are not excluded or unnecessarily discouraged from taking part.

There has been a huge shift towards patient-centred approaches in dementia research with the increased involvement of patient participation involvement groups as it is recognised that the goodwill of participant groups is enhanced by a positive research experience and hindered by a poor one. Therefore, a great deal of consideration has been given to factors that may influence participant burden.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:

There are no comments in regards to this article.

 You must be a member of the site to make a comment.
About the author

Shani McCoy has worked in research delivery for the R&D department at Berkshire Healthcare Foundation Trust for a total of five years. Prior to this, she worked on a number of her own research studies both behavioural and neuroscience-based. Shani currently works in the trust as a Clinical Research Practitioner for the Memory and Cognition Research Unit based at the University of Reading, UK, delivering a variety of research protocols in the field of dementia and neurodegenerative disorders. She is a member of Join Dementia Lead for Berkshire, which is the national dementia research database of the NIHR.
Print this page
Send to a friend
Privacy statement
News and Press Releases

Axol Bioscience introduces multi-electrode array screening services for human iPSC-derived cells

• Expansion of Axol Bioscience’s service offering for pre-clinical drug discovery • New services combine the Company’s iPSC-derived human cells and electrophysiological expertise with Axion Biosystems’ Maestro Pro MEA platform
More info >>

White Papers

Autoinjector testing made safe efficient and flexible


The autoinjector market is one of the fastest growing markets across almost all pharmaceutical applications. Studies expect a global market volume of approximately USD 2.5 billion by 2020, with pre-filled autoinjectors representing the largest market segment. There are a variety of tests that can be performed on autoinjectors, and these are well-demonstrated by the Zwick product portfolio. The Ulm-based company and specialist in testing systems offers a variety of testing systems that are already being successfully used by multiple pharmaceutical companies.
More info >>

Industry Events

Clinical Operations in Oncology Trials West Coast

17-18 November 2020, Hilton San Francisco Airport Bayfront

Clinical Operations in Oncology Trials West Coast will be returning this April for another 2 day event full of thought-provoking presentations, discussions and roundtables. This years' conference highlights include the high-level, interactive immuno-oncology discussion panel where specialists from Shasta Bio Ventures, Abbvie and BeiGene shared their top tips on how to run successful and impactful immuno-oncology studies.
More info >>



©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement